Wednesday 28 May 2025

Pharma & Biotech Start-up & Scale-up News

Featured

Prothena
Prothena is an Irish clinical-stage biotechnology company that develops novel monoclonal antibodies directed towards misfolded proteins or improper cell adhesion.
Pharmaceutical
Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk
28 March 2025
Pharmaceutical
Lexicon pivots back to pipeline after FDA rejection
25 November 2024

Latest Ones To Watch News

Biotechnology
Biogen and City Therapeutics collaborate on RNAi meds
27 May 2025
Pharmaceutical
Syndeio debuts with $90 million and a synapse-first approach
27 May 2025
Pharmaceutical
MC2 Therapeutics appoints Trine Ahlgreen as new CEO
27 May 2025
More ones to watch news >
Reset all filters
Refine Search
Tubulis
Tubulis
Neurocrine Biosciences
Axsome Therapeutics
Cidara Therapeutics
Halda Therapeutics
Opthea
OncoZenge
Soleno Therapeutics
GAIA
Alligator Bioscience
Pliant Therapeutics
Nuvation Bio
Enanta Pharmaceuticals
Basilea
Exsilio Therapeutics
Aphaia Pharma
Avextra
Aurion Biotech
āshibio
UTILITY Therapeutics


Today's issue

ImCheck data at ASCO points to promise for T-cell therapy in AML
Biotechnology
ImCheck data at ASCO points to promise for T-cell therapy in AML
27 May 2025
Biotechnology
Hansa to cut staff by 20% in bid to streamline operations
27 May 2025
Biotechnology
ADCs forecast to capture $3.9 billion NSCLC market by 2032
27 May 2025
Biotechnology
FDA pauses Rocket’s Phase II trial of RP-A501 for Danon disease
27 May 2025
Biotechnology
China's biopharma commands $30 billion in oncology licensing deals
27 May 2025
Biotechnology
Biogen and City Therapeutics collaborate on RNAi meds
27 May 2025
Pharmaceutical
Zuellig Pharma launches Lilly’s Mounjaro in Thailand
27 May 2025

Company Spotlight

Prothena is an Irish clinical-stage biotechnology company that develops novel monoclonal antibodies directed towards misfolded proteins or improper cell adhesion.




Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze